5 hrs ago
Sequenom: Plenty Of Room To Run
Scope: Upside potential is ~50%; downside risk is ~15%. Context: Market has not appreciated the non-linear growth phase that Sequenom is in.
Thu May 16, 2013
Sequenom's Management Presents at Bank of America Merrill Lynch Health Care Conference
Our next company and closing out our healthcare conference will be Sequenom. Speaking today from the company will be Paul Maier, Chief Financial Officer and Dirk van den Boom, Executive Vice President - R&D and Chief Technology Officer.
Mon May 13, 2013
Sequenom shares advance as analyst lifts rating Shares of Sequenom...
Shares of Sequenom Inc. extended their recent gains Monday after a Credit Suisse analyst upgraded the stock, citing expanded insurance coverage for its MaterniT21 Plus Down syndrome test.
Sequenom Upgraded to "Neutral" at Credit Suisse
The firm currently has a $4.50 target price on the stock, up from their previous target price of $4.00. Shares of Sequenom traded up 5.69% during mid-day trading on Monday, hitting $4.27. Sequenom has a one year low of $2.65 and a one year high of $5.83. The stock's 50-day moving average is currently $4.14. The company's market cap is $491.2 ... (more)
Large Cap Movers
Jackpotpennystocks.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:- Sequenom, Inc.
Sun May 12, 2013
5 Stocks This Growth-Oriented Hedge Fund Is Most Committed To
Bluefin Investment Management is a value-oriented hedge fund founded and managed by Brian K. Russell.
Sat May 11, 2013
Xoma Corp (XOMA), WebMD Health Corp. (WBMD), and Sequenom, Inc....
Few sectors see as many stocks gaining in the double-digits each week as health care.
Fri May 10, 2013
Midday movers: Molycorp, True Religion, Pfizer
Two of Dell's largest shareholders, Carl Ichan and Southeastern Asset Management, told the company's board they will vote against its plan to go private.
Thu May 09, 2013
Sequenom's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Hello. Welcome to Sequenom, Inc. First Quarter 2013 Earnings Conference Call. All participants will be in a listen-only mode.
Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
Sequenom, Inc. , a life sciences company providing innovative genetic analysis solutions, today reported revenue of $38.5 million for the first quarter of 2013, an increase of 158% compared to revenue of $14.9 million for the first quarter of 2012.
Wed May 08, 2013
Leveraging Sequenom's Upcoming Earnings Volatility
Since my last article analyzing Sequenom's financials and modeling its forward performance here , the stock has trended down fairly strongly.
Sequenom Announces Participation At The Bank Of America Merrill Lynch Health Care Conference
The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com . An audio replay will be available for 30 days following the initial presentation web cast.
Mon Apr 29, 2013
Arrayit Corporation , a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide, has been a leader in the microarray market for some time, having been featured on popular documentaries like PBS' NOVA series.
Tue Apr 23, 2013
4 lessons from a failed IBM-Roche collaboration
There's been plenty of great press -- you might even say hype -- about IBM's "DNA transistor," a new type of gene sequencing technology that had come out of the company's labs.